Navigation Links
Linchpin gene may be useful target for new breast cancer therapies
Date:9/16/2007

University of Iowa researchers have discovered a gene that plays a linchpin role in the ability of breast cancer cells to respond to estrogen. The finding may lead to improved therapies for hormone-responsive breast cancers and may explain differences in the effectiveness of current treatments.

Estrogen causes hormone-responsive breast cancer cells to grow and divide by interacting with estrogen receptors made by cancer cells. Interfering with estrogen signaling is the basis of two common breast cancer therapies -- tamoxifen, which blocks estrogen's interaction with a primary estrogen receptor called ER-alpha, and aromatase inhibitors that reduce the amount of estrogen the body makes and therefore affect any pathway that uses estrogen.

The study, led by Ronald Weigel, M.D., Ph.D., professor and head of surgery at the University of Iowa Roy J. and Lucille A. Carver College of Medicine, reveals a central role for transcription factor AP2C (TFAP2C) in controlling multiple pathways of estrogen signaling. The findings are published in the Sept. 15 issue of Cancer Research.

"Estrogen binds to estrogen receptors and triggers a cascade of events including gene regulation," said Weigel, who also is a member of the Holden Comprehensive Cancer Center at the UI. "We found that elimination of the TFAP2C from the cell causes all of those cascades that we associate with estrogen to go away. The treated cancer cells were not able to respond to estrogen by any normal pathway."

The researchers found that silencing expression of TFAP2C in hormone-responsive breast cancer cells significantly decreased the amount of ER-alpha made by the cancer cell. This reduction in ER-alpha (down to 16 percent of the level normally made by breast cancer cells) also affected production of other "downstream" genes involved in cancer growth.

In addition, silencing the TFAP2C also knocked out expression of another estrogen receptor called GPR30 that is
'/>"/>

Contact: Jennifer Brown
jennifer-l-brown@uiowa.edu
319-335-9917
University of Iowa
Source:Eurekalert

Page: 1 2

Related biology news :

1. UCSD discovery may provide novel method to generate medically useful proteins
2. Scientists fetch useful information from dog genome publications
3. One-of-a-kind imaging probe reveals secrets useful for drug discovery
4. Scientists seek useful traits in wild cottons
5. Dual-imaging technique useful before -- and during -- brain surgery
6. New binding target for oncogenic viral protein
7. Ancient olfaction protein is shared by many bugs, offering new pest control target
8. Novel Enzyme Shows Potential As An Anti-HIV Target
9. A bacterial genome reveals new targets to combat infectious disease
10. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
11. Researchers identify target for cancer drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... October 16, 2014 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... technologies including Wocket™, the Smart Wallet, at the 13 ... is a leading global conference on the intersection of ... Mark Anderson , founder and publisher of the ...
(Date:10/15/2014)... from strains of influenza virus increases with the latest ... complacent that the most substantial threats have been identified, ... arise when a new virus strain – against which ... in the human population. There have been five such ... which – the 1918 Spanish Flu – cost 50 ...
(Date:10/15/2014)... The German Gauß-Allianz has admitted Johannes Gutenberg University ... the Rhineland-Palatinate science hub continues to maintain a ... computing. , "The acceptance of Johannes Gutenberg ... Gauß-Allianz is a milestone in the national and ... support. The state of Rhineland-Palatinate can be proud ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... and Honorary Lecturer in Cardiovascular Medicine at The University of ... only location in the UK where the trial is taking ... manufacturer, to take part in the trial as he specialises ... attacks. The other trial sites are in Australia, Belgium, ...
... the Joint Annual Meeting of the American Dairy Science Association ... take place in Indianapolis, IN from July 8 to 12, ... symposia on topics such as animal genetics, food science and ... a hands-on media training workshop on July 12. Animal ...
... are thrown away each year because the ,best before, ... cautious estimate, which means a lot of still-edible food ... packaging could ,test, whether the contents are still safe ... di Catania, CEA-Liten and STMicroelectronics have invented a circuit ...
Cached Biology News:Manchester patients take part in pioneering heart attack blood test trial 2Invention opens the way to packaging that monitors food freshness 2Invention opens the way to packaging that monitors food freshness 3
(Date:10/20/2014)... -- GenVec, Inc. (NASDAQ: GNVC ) today announced the ... board of directors effective on October 24, 2014.   Dr. Horovitz ... its chairman from June 2006 to November 2013.  During his ... and Audit Committees of the board.  "We ... service to GenVec, and its stockholders," said Wayne T. ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Partners LLC, announced today that Ellen Teplitzky, an ... support for the pharmaceutical industry, has joined the ... of its legal services practice. NDA Partners ... expert witness and testimony, to top law firms ...
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
(Date:10/19/2014)... October 19, 2014 The Asian Automatic ... Asian with analysis and forecast of revenue. The Automatic ... to around $463.9 million by 2018, at a developing ... through the TOC of the Asian Automatic patient billing ... provided. This also provides a glimpse of the segmentation ...
Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... BRISBANE, Australia and SAN CLEMENTE, Calif., Oct. ... medical applications of bioimpedance,technology and Metagenics, Inc., ... foods, and therapeutic lifestyle change,programs, today announced ... United States and Canada. Metagenics, Australian affiliate, ...
... 6, 2008 at 3:00 p.m. EDT, ... Inc., a,biopharmaceutical company developing genetically-targeted therapies for,heart ... that,Richard Brewer, the company,s president and chief ... chairman and chief science and medical,officer, will ...
... Clarient, Inc.,(Nasdaq: CLRT ), a premier ... oncologists and the pharmaceutical industry,today announced that the ... interview on WallSt.net,s 3-Minute Press Show., The ... and the,significance of the company,s latest press release., ...
Cached Biology Technology:ImpediMed and Metagenics Announce Agreement 2ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 2ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 3ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 4ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 5[video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.net's 3-Minute Press Show 2
... SYBR Safe DNA gel stain was developed ... than ethidium bromide for staining DNA in agarose ... only less mutagenic than ethidium bromide but SYBR ... of ethidium bromide. SYBR Safe stain comes as ...
... Service enables scientists who do not have access ... to have their biological samples tested for the ... easy as 1-2-3 Chose the analytes ... from the S&S antibody menu. Send your ...
... I nucleic acid gel stain is an ... bright fluorescence when bound to dsDNA and low ... dsDNA in gels using laser scanners or standard ... has also found uses in capillary electrophoresis, real-time ...
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic gel acid stain has also found ... bandshift assays. One mL stains 100 minigels. A ...
Biology Products: